- Home
- HRZN vs CELC Comparison
HRZN vs CELC Comparison
Compare HRZN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRZN
- CELC
- Stock Information
- Founded
- HRZN 2008
- CELC 2011
- Country
- HRZN United States
- CELC United States
- Employees
- HRZN N/A
- CELC N/A
- Industry
- HRZN Finance/Investors Services
- CELC Medical Specialities
- Sector
- HRZN Finance
- CELC Health Care
- Exchange
- HRZN Nasdaq
- CELC Nasdaq
- Market Cap
- HRZN 341.0M
- CELC 391.0M
- IPO Year
- HRZN 2010
- CELC 2017
- Fundamental
- Price
- HRZN $9.47
- CELC $9.29
- Analyst Decision
- HRZN Hold
- CELC Strong Buy
- Analyst Count
- HRZN 4
- CELC 6
- Target Price
- HRZN $9.56
- CELC $30.17
- AVG Volume (30 Days)
- HRZN 355.4K
- CELC 260.9K
- Earning Date
- HRZN 03-04-2025
- CELC 05-14-2025
- Dividend Yield
- HRZN 13.94%
- CELC N/A
- EPS Growth
- HRZN N/A
- CELC N/A
- EPS
- HRZN N/A
- CELC N/A
- Revenue
- HRZN $99,915,000.00
- CELC N/A
- Revenue This Year
- HRZN $12.95
- CELC N/A
- Revenue Next Year
- HRZN $8.81
- CELC N/A
- P/E Ratio
- HRZN N/A
- CELC N/A
- Revenue Growth
- HRZN N/A
- CELC N/A
- 52 Week Low
- HRZN $8.46
- CELC $8.50
- 52 Week High
- HRZN $12.63
- CELC $20.89
- Technical
- Relative Strength Index (RSI)
- HRZN 54.27
- CELC 35.82
- Support Level
- HRZN $9.27
- CELC $9.98
- Resistance Level
- HRZN $9.36
- CELC $10.91
- Average True Range (ATR)
- HRZN 0.15
- CELC 0.74
- MACD
- HRZN 0.03
- CELC -0.01
- Stochastic Oscillator
- HRZN 88.89
- CELC 29.59
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services and sustainability industries.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.